1-Bromoheptane | CAS:629-04-9

We serve 1-Bromoheptane CAS:629-04-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Bromoheptane

Chemical Name:1-Bromoheptane
CAS.NO:629-04-9
Synonyms:Heptyl bromide
1-bromo-heptane
Heptane,1-bromo
n-Heptyl bromide
Molecular Formula:C7H15Br
Molecular Weight:179.09800
 
Physical and Chemical Properties:
Density:1.14;
Melting point:-58oC;
Boiling point:180oC;
Flash point:141oF;
Index of Refraction:1.4499;
 
Specification:
Appearance:Colorless clear liquid
Purity(GC):≥99.0%
Moisture:≤0.1%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Synthesis:Prepared by reacting 1-Heptanol with hydrobromic acid or sodium bromide
Application:As a solvent and an intermediate in organic synthesis



Contact us for information like 1-Bromoheptane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-Heptyl bromide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Heptane,1-bromo Use and application,1-Bromoheptane technical grade,usp/ep/jp grade.


Related News: Coupled with the poor global pesticide industry situation this year, the weakening of downstream customer demand has affected the sales of pesticide intermediates.2,4,5-Trifluorotrichloromethyl benzene manufacturer API and raw material are often confused due to the similar usage of the two terms.4-Methyl-3-nitrophenol supplier The travel restrictions will take effect on Tuesday, Prime Minister Chung Sye-kyun said, as the number of people testing positive for the coronavirus in South Korea increased to 15.6-Methoxy-5-methylpyridin-3-amine vendor The travel restrictions will take effect on Tuesday, Prime Minister Chung Sye-kyun said, as the number of people testing positive for the coronavirus in South Korea increased to 15.Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.